"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
Please provide your email address to receive an email when new articles are posted on . In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic ...
(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Merin, director of the leukemia program at Cedars-Sinai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results